Skip to main content
. 2013 May 6;5(2):511–518. doi: 10.3390/cancers5020511

Table 2.

Progression and infusion-related reactions in patients after receiving sipuleucel-T.

Progression and infusion-related reactions
Progression (%) 72.2
Rapid Progression (%) 19.4
Median days to progression (range)
 Overall 158 (71–367)
 Rapid progression group 104 (71–111)
 Non-rapid progression group 168 (124–367)
Infusion-related reaction (%) 8.3